- The FDA has approved Abbott Laboratories (NYSE:ABT) latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
- The Navitor TAVI system is the latest addition to the company’s comprehensive transcatheter structural heart portfolio, offering less invasive treatment options.
- Aortic stenosis occurs when the aortic valve’s opening narrows, restricting blood flow to the body. Left untreated, it can lead to heart failure and death.
- Navitor features a unique fabric cuff (NaviSeal) to reduce or eliminate the backflow of blood around the valve frame, known as a paravalvular leak (PVL).
- Additionally, the new device is the only self-expanding TAVI system with leaflets within the native valve; this design can help improve access to coronary arteries to facilitate future procedures for treating coronary artery disease.
- The Navitor device is implanted using Abbott’s FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable, and accurate valve delivery and placement.
- Price Action: ABT shares are down 0.04% at $113.47 on the last check Tuesday.
Altria FY23 Adj. EPS Outlook $4.98 – $5.13 Vs. $5.00 Est
We expect our 2023 full-year adjusted diluted EPS to be in a range of $4.98 to $5.13, representing a growth rate of 3% to 6% from an adjusted diluted EPS base of $4.84 in 2022. While the 2023 full-year adjusted diluted
